Nippon Shinyaku Co., Ltd. (TYO:4516)
3,312.00
-39.00 (-1.16%)
May 15, 2025, 3:30 PM JST
Nippon Shinyaku Revenue
In the fiscal year ending March 31, 2025, Nippon Shinyaku had annual revenue of 160.23B JPY with 8.08% growth. Nippon Shinyaku had revenue of 38.91B in the quarter ending March 31, 2025, with 9.53% growth.
Revenue
160.23B
Revenue Growth
+8.08%
P/S Ratio
1.39
Revenue / Employee
72.40M
Employees
2,213
Market Cap
223.16B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 160.23B | 11.98B | 8.08% |
Mar 31, 2024 | 148.26B | 4.08B | 2.83% |
Mar 31, 2023 | 144.18B | 6.69B | 4.87% |
Mar 31, 2022 | 137.48B | 15.60B | 12.80% |
Mar 31, 2021 | 121.89B | 5.25B | 4.50% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Chugai Pharmaceutical | 1,222.12B |
Takeda Pharmaceutical Company | 4,581.55B |
Daiichi Sankyo Company | 1,886.26B |
HOYA Corporation | 869.37B |
Terumo | 1,011.15B |
Otsuka Holdings | 2,393.18B |
Astellas Pharma | 1,912.32B |
Olympus | 997.33B |
Nippon Shinyaku News
- 4 months ago - Regenxbio Secures A Partnership With Nippon Shinyaku For RGX-111 & 121 - Seeking Alpha
- 4 months ago - REGENXBIO partners with Nippon Shinyaku for MPS therapies - Seeking Alpha
- 4 months ago - Why KB Home Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Benzinga
- 8 months ago - Week In Review: Nippon Shinyaku Signs $735m Deal For DMD Therapy - Seeking Alpha
- 8 months ago - Capricor Therapeutics partners with Nippon Shinyaku for European commercialization of Deramiocel - Seeking Alpha
- 8 months ago - EXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm - Benzinga